Hamburg, February 7, 2025

We are pleased that our development project for an innovative drug against severe malaria is being supported with the tax research allowance!

The tax research allowance is a government subsidy for companies that invest in research and development (R&D). Companies that carry out innovative projects - in the fields of technology, medicine or other sciences - can have their R&D costs partially reimbursed by the German state in the form of the research allowance. 

The development of the new malaria drug based on a combination of short-term active substances for the treatment of severe and cerebral malaria is one of the core projects of Hamburg-based DMG Deutsche Malaria GmbH.

Severe malaria and cerebral malaria are two serious complications of malaria infection caused by the unicellular parasitic pathogen Plasmodium falciparum. Severe malaria is a life-threatening condition characterised by a high parasite load and organ failure. It can affect various organs.

Cerebral malaria is a special form of severe malaria that affects the brain. It occurs when infected red blood cells clump together and forming clots in the small blood vessels of the brain, leading to inflammation and circulatory problems. Cerebral malaria is one of the most dangerous complications, as it can lead to permanent damage or even death despite treatment.

The new drug from DMG Deutsche Malaria GmbH consists of a combination of fosmidomycin, artesunate and clindamycin in an injection solution for the rapid treatment of severe forms of malaria, particularly in children. It has already demonstrated a high level of safety and efficacy in a completed clinical trial.

Research is expensive and associated with risks. The research grant helps to overcome these challenges and bring innovative ideas forward more quickly. Thanks to this supportive funding, we can pursue our goal of developing our effective drug against severe forms of malaria with even greater commitment. 

With this support, we will continue on our path to create breakthrough solutions for a better future. 

Enquiries should be addressed to Dr David Hutchinson, Managing Director, DMG Deutsche Malaria GmbH at: d[email protected]